本帖最后由 老马 于 2012-1-13 21:20 编辑
6 R, y, u$ b: `/ e3 q8 o0 {
8 g7 `, U$ i b2 |8 c爱必妥和阿瓦斯丁的比较
; q7 {0 k) o, _9 P. d* {+ H [
' t5 p+ q( I/ ]# h4 ^4 e7 w# D& `. M
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' h8 j: i# s+ {) ]
0 U5 g5 s9 p: A- C$ |+ K$ h
: F* Q/ G" y! x
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/- H- b$ {. [% K: n: n @" U. j4 S
==================================================
8 @+ b6 q( v) WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) T( C8 f0 {: Z6 R pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 b0 A# c1 ^) i+ i% k. X9 R& w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( g$ F% R, M+ Y6 z( ~: p M
|
显身卡
